Search

Your search keyword '"Sanjak, M."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Sanjak, M." Remove constraint Author: "Sanjak, M."
42 results on '"Sanjak, M."'

Search Results

2. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

3. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

4. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study

5. Eculizumab Improves Fatigue in Refractory Generalized Myasthenia Gravis

6. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

8. Assessment of disease progression in dysferlinopathy: a 1-year cohort study

9. Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

11. Does the performance of upper limb capture functional variations in dysferlinopathy?

13. Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology

15. Development and Deployment of Performance Measures Based on American Academy of Neurology (AAN) Amyotrophic Lateral Sclerosis (ALS) Guidelines To Assess Provider Implementation, Patient Acceptance and Patient Adherence of Evidence-Based Recommendations at the Carolinas Neuromuscular/ALS-MDA Center: Accountability Assessment According to the Joint Commission (TJC) Disease Specific Certification (DSC) Protocol - The First Year (P01.106)

23. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

25. Assessment of disease progression in dysferlinopathy: A 1-year cohort study.

26. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis.

27. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.

28. Exercise-induced neuroplasticity in human Parkinson's disease: What is the evidence telling us?

29. Vestibular deficits leading to disequilibrium and falls in ambulatory amyotrophic lateral sclerosis.

30. Quality improvement in neurology: amyotrophic lateral sclerosis quality measures. Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

31. Parkinson patients as partners in care.

32. Surgeon fatigue and postural stability: is robotic better than laparoscopic surgery?

33. Promoting exercise in Parkinson's disease through community-based participatory research.

34. Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study.

35. Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis.

36. Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: preliminary data for evidence-based guidelines.

37. Disease-modifying drug therapies.

38. Measurement of strength: pro.

40. Design of clinical therapeutic trials in amyotrophic lateral sclerosis.

41. Endurance training does not affect diaphragm mitochondrial respiration.

42. Role of muscular exercise in amyotrophic lateral sclerosis.

Catalog

Books, media, physical & digital resources